Evaluation of Clinical Outcomes of Riluzole monotherapy and Riluzole based adjunctive interventions in Amyotrophic Lateral Sclerosis: A meta analytic and unsupervised clustering approach
Rathore, H. S.; Brar, J. S.; Gupta, S.; Dalla, N.; Kumar, S.; Rathore, H. S.; Banerjee, D.; Kumar, S.
Show abstract
Amyotrophic Lateral Sclerosis (Lou Gehrigs disease) is a progressive neurodegenerative disease affecting hundreds of thousands of people worldwide. It is characterized by the degeneration of the neurons in the brain and spinal cord of the patients, leading to a loss of control of muscles. Over time, without nerves to stimulate them muscles tend to atrophy. ALS may occur sporadically or run in families; many mutations have been identified for the latter. Treatment of ALS is mostly limited to three approved therapeutic agents: riluzole, edaravone, and tauroursidiol/ sodium phenylbutyrate. Among these, riluzole remains the most effective despite its early discovery. There are no conclusive meta-analysis comparing riluzole monotherapy to all possible co-therapies present. In this work we have attempted to address such a concern and observed that no adjunct therapy significantly improved the performance of riluzole. However, mitochondrial/ oxidative stress modulator and neuroimmune/ neuroexcitability modulator co-therapy exhibited positive trends. Surprisingly, trials were mainly confined to the USA and European countries, indicating unequal demographic representation in ASL research. We have concluded that large double blinded inter-continental RCTs to be carried out for better understanding of the scenario.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The oligogenic structure of amyotrophic lateral sclerosis has genetic testing, counselling, and therapeutic implications 92%
- Low lymphocyte count is a risk factor for Parkinsons disease 92%
- Spinal Cord Motor Neuron Phenotypes and Polygenic Risk Scores in Sporadic Amyotrophic Lateral Sclerosis: Deciphering the Disease Pathology and Therapeutic Potential of Ropinirole Hydrochloride 91%
Similar papers in this journal
- Current status and future opportunities in modeling Multiple Sclerosis clinical characteristics 93%
- A Phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design and baseline data 91%
- Factors Impacting Quality of Life in Multiple System Atrophy 91%
Similar papers in this journal
- Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts’ study 95%
- Peripherin: a novel early diagnostic and prognostic plasmatic biomarker in Amyotrophic Lateral Sclerosis 93%
- Diagnostic accuracy of cerebrospinal fluid and blood biomarkers for the differential diagnosis of sporadic Creutzfeldt-Jakob disease: a (network) meta-analysis 91%
Similar papers in this journal
- Acetyl-L-leucine for Niemann-Pick type C – a multi-national, rater-blinded phase II trial 93%
- Assessment of the Reliability, Responsiveness, and Meaningfulness of the Scale for the Assessment and Rating of Ataxia (SARA) for Lysosomal Storage Disorders 93%
- The role of age in choosing high-efficacy treatment for multiple sclerosis - an Austrian MS Database study 92%
Similar papers in this journal
- A low molecular weight dextran sulphate, ILB(R), for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial 94%
- Masitinib Limits Neuronal Damage, as Measured by Serum Neurofilament Light Chain Concentration, in a Model of Neuroimmune-Driven Neurodegenerative Disease 93%
- Device-aided therapies (DATs) in Parkinson’s disease (PD). The DATs-PD GETM Spanish Registry Protocol Study 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.